PDS Biotechnology (NASDAQ:PDSB) Releases Earnings Results

PDS Biotechnology (NASDAQ:PDSB) issued its quarterly earnings results on Thursday. The company reported ($0.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.08, Zacks reports.

PDS Biotechnology Price Performance

PDS Biotechnology stock opened at $1.25 on Friday. The company has a market capitalization of $47.74 million, a PE ratio of -1.08 and a beta of 1.68. The company has a current ratio of 2.84, a quick ratio of 2.84 and a debt-to-equity ratio of 0.55. The stock has a 50-day moving average price of $1.41 and a two-hundred day moving average price of $2.17. PDS Biotechnology has a 12 month low of $1.13 and a 12 month high of $4.56.

Analyst Ratings Changes

Separately, HC Wainwright dropped their target price on shares of PDS Biotechnology from $21.00 to $13.00 and set a “buy” rating for the company in a report on Thursday. One investment analyst has rated the stock with a sell rating, three have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, PDS Biotechnology presently has a consensus rating of “Moderate Buy” and a consensus price target of $9.00.

PDS Biotechnology Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.